“showed a trend”

Subgroup analysis of patients ≥60 years showed a trend toward improved 2-year OS with fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI) versus fludarabine/busulfan: 71% versus 53% (HR = 0.47, p = 0.121).

Ogg1-KO mice fed LFD showed a trend toward lower lean body mass ( p = 0.1218, Supplementary Figure S1B ) and higher fat mass ( p = 0.1231, Supplementary Figure S1C ) compared to WT/LFD mice although neither difference was significant.

Although not statistically significant, gSF mice showed a trend toward greater expansion of dominant T cell clones, compared to gSC mice ( p = 0.1219) (Fig. 5e ).

Adjusted for SINS, high-grade compression showed a trend toward increased mortality (HR: 2.3; 95% CI: 0.8–6.3; P = 0.122).

Children on blended diets showed a trend of weaning quicker (46.15 +/‐ 30.0) than children on formula (62.8 +/‐ 57.1; p=.122).

The 20- and 80-mg dose groups did not demonstrate a significant difference in all-cause mortality or MI incidence from the placebo group at 36 days, whereas the 120 mg dose group showed a trend toward a 10 % risk reduction ( P = 0.122) [ 163 ].

230 ng/mL, P = 0.0019) and showed a trend towards higher levels than patients with dilated cardiomyopathy (515 vs. 252 ng/mL, P = 0.1224) ( 29 ).

Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123).

A BMI below 25 kg/m2 was associated with a trend toward higher success rates (adjusted OR, 1.706; 95% CI, 0.728-4.000; P =0.219), whereas patients with hematologic malignancies showed a trend toward lower success rates (adjusted OR, 0.574; 95% CI, 0.283-1.163; P =0.123), though these associations were not statistically significant. 4.

Higher CD14+CD11c+HLA-DR+ monocyte level was significantly associated with poor OS (HR 1.06, 95% CI 1.00-1.13, P = 0.043) while Foxp3+CD4+ regulatory T-cell level showed a trend towards better PFS (HR 0.89, 95% CI 0.77-1.03, P = 0.123).

Survival analysis taking into consideration only the sub-group of KIT and PDGFRA mutated cases showed a trend to a worse OS ( p = 0.123) and DFS ( p = 0.099) ( Supplementary Figure 4 ) of Group II compared to Group I.

BMI showed a trend toward modifying leptin deficiency associations, with enhanced inverse effects at lower BMI levels for MASLD (interaction RRR 0.89, 95% CI 0.77–1.03, p = 0.123), though confidence intervals included unity.

Although LC3B-II/LC3B-I ratios showed a trend towards an increase, these changes were not significant (3 hr, p = 0.1237; 6 hr, p = 0.2776; 12 hr, p = 0.0857; 24 hr, p = 0.7543) ( Fig 2D ).

When analyzed separately, neither group showed statistically significant differences across doses, though the 10.0 mg/kg dose showed a trend toward reduction in both groups ( p = 0.124 in low responders, p = 0.066 in high responders).

Maximal flow was reduced and showed a trend of being more obstructed with 200 μM NAD + flush ( p = 0.124, Figure 3 C) than in the control group, whereas 100 μM NAD + flush was comparable ( p = 0.390, Figure 3 C).

The stent group showed a trend towards a higher incidence of symptomatic intracranial haemorrhage (11.0% vs 4.2%; OR 2.22, 95% CI 0.80 to 6.14, p=0.124).

No factors were found to have prognostic relevance in the patients’ serum, though high IL-6 levels showed a trend to be associated with worse prognosis ( p = 0.124) (Figure 1A ).

Preliminary data showed a trend toward a survival benefit in the experimental arm with a median OS of 16.07 months, compared to 14.88 months in the control group (HR 0.79, p = 0.1244).

29 By contrast, the Late Group showed a trend towards an increase in the LVMI, which was not significant (p=0.125).

In contrast, DRE males showed a trend towards elevated CCL2 ( p = 0.125) and CCL5 ( p = 0.066) compared to healthy males (Fig. 3 G,H).

Patients with TBI showed a trend towards elevated PER2 ( OR = 3.00 [0.84–9.33], P = 0.125) , but not towards delirium occurrence ( P = 0.556).

The latter showed a trend towards a decreased 5-year survival rate ( p = 0.125).

Comparison between sub-groups at 4-weeks showed a trend in favor of the IG-FM compared to the PG-FM (mean difference = 1.39, p = 0.125, d = 2.257, Table 3 ).

Males showed a trend to sing fewer syllable types within a song after SD than after a baseline night ( emmeans : β ± s.e = −0.132 ± 0.049, d.f. = 5.99, t = −2.691, p = 0.125), while females showed no differences in syllable types ( emmeans : β ± s.e = 0.085 ± 0.079, = 19.59, t = 1.076, p = 0.708).

Fasting GLP-1 levels showed a trend toward an increase in the F group, almost doubling compared with baseline values (25.5 ± 9.9 vs. 41.7 ± 12.6 pmol/L; p = 0.126), while peak GLP-1 levels were significantly higher compared to NF (41.5 ± 10.1 vs. 69.7 ± 29.9 pmol/L; p = 0.03; Fig. 4 B; Table 2 ).